Literature DB >> 19266143

Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease.

Susie M D Henley1, Edward J Wild, Nicola Z Hobbs, Rachael I Scahill, Gerard R Ridgway, David G Macmanus, Roger A Barker, Nick C Fox, Sarah J Tabrizi.   

Abstract

Huntington's disease (HD) is caused by an expanded CAG repeat on the gene encoding for the protein huntingtin. There are conflicting findings about the extent to which repeat length predicts signs of the disease or severity of disease progression in adults. This study examined the relationship between CAG repeat length and brain volume in a large cohort of pre- and post-motor onset HD gene carriers, using voxel-based morphometry (VBM), an approach which allowed us to investigate the whole brain without defining a priori regions of interest. We also used VBM to examine group differences between 20 controls, 21 premanifest, and 40 early HD subjects. In the 61 mutation-positive subjects higher CAG repeat length was significantly associated with reduced volume of the body of the caudate nucleus bilaterally, left putamen, right insula, right parahippocampal gyrus, right anterior cingulate, and right occipital lobe, after correcting for age. The group contrasts showed significant reduction in grey matter volume in the early HD group relative to controls in widespread cortical as well as subcortical areas but there was no evidence of difference between controls and premanifest subjects. Overall we have demonstrated that increased CAG repeat length is associated with atrophy in extra-striatal as well as striatal regions, which has implications for the monitoring of disease-modifying therapies in the condition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19266143     DOI: 10.1007/s00415-009-0052-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  36 in total

1.  Huntington disease: clinical care and evaluation.

Authors:  I Shoulson; S Fahn
Journal:  Neurology       Date:  1979-01       Impact factor: 9.910

2.  Does CAG repeat number predict the rate of pathological changes in Huntington's disease?

Authors:  A Rosenblatt; R L Margolis; M W Becher; E Aylward; M L Franz; M Sherr; M H Abbott; K Y Lian; C A Ross
Journal:  Ann Neurol       Date:  1998-10       Impact factor: 10.422

3.  Clinical presentation and patterns of regional cerebral atrophy related to the length of trinucleotide repeat expansion in patients with adult onset Huntington's disease.

Authors:  K Sieradzan; D M Mann; A Dodge
Journal:  Neurosci Lett       Date:  1997-03-28       Impact factor: 3.046

4.  Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain.

Authors:  Peggy F Shelbourne; Christine Keller-McGandy; Wenya Linda Bi; Song-Ro Yoon; Louis Dubeau; Nicola J Veitch; Jean Paul Vonsattel; Nancy S Wexler; Norman Arnheim; Sarah J Augood
Journal:  Hum Mol Genet       Date:  2007-04-04       Impact factor: 6.150

5.  Variation of selective gray and white matter atrophy in Huntington's disease.

Authors:  Robert Jech; Jirí Klempír; Josef Vymazal; Jana Zidovská; Olga Klempírová; Evzen Růzicka; Jan Roth
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

6.  The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy.

Authors:  D M Mann; R Oliver; J S Snowden
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

7.  Regional specificity of brain atrophy in Huntington's disease.

Authors:  G M Halliday; D A McRitchie; V Macdonald; K L Double; R J Trent; E McCusker
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

8.  Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease.

Authors:  S Furtado; O Suchowersky; B Rewcastle; L Graham; M L Klimek; A Garber
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

9.  Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease.

Authors:  S M de la Monte; J P Vonsattel; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1988-09       Impact factor: 3.685

10.  Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI.

Authors:  Rachael I Scahill; Jonathan M Schott; John M Stevens; Martin N Rossor; Nick C Fox
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

View more
  21 in total

1.  Language deficits in pre-symptomatic Huntington's disease: evidence from Hungarian.

Authors:  Dezso Nemeth; Cristina D Dye; Tamás Sefcsik; Karolina Janacsek; Zsolt Turi; Zsuzsa Londe; Péter Klivenyi; Zsigmond Tamás Kincses; Nikoletta Szabó; László Vecsei; Michael T Ullman
Journal:  Brain Lang       Date:  2012-04-24       Impact factor: 2.381

2.  A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study.

Authors:  H Diana Rosas; Martin Reuter; Gheorghe Doros; Stephanie Y Lee; Tyler Triggs; Keith Malarick; Bruce Fischl; David H Salat; Steven M Hersch
Journal:  Mov Disord       Date:  2011-05-24       Impact factor: 10.338

3.  Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntington's disease.

Authors:  Robert Christian Wolf; Philipp Arthur Thomann; Fabio Sambataro; Nadine Donata Wolf; Nenad Vasic; G Bernhard Landwehrmeyer; Sigurd Dietrich Süßmuth; Michael Orth
Journal:  J Neurol       Date:  2015-01-28       Impact factor: 4.849

Review 4.  Huntington disease: natural history, biomarkers and prospects for therapeutics.

Authors:  Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi
Journal:  Nat Rev Neurol       Date:  2014-03-11       Impact factor: 42.937

5.  Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease.

Authors:  Dan Wu; Andreia V Faria; Laurent Younes; Susumu Mori; Timothy Brown; Hans Johnson; Jane S Paulsen; Christopher A Ross; Michael I Miller
Journal:  Hum Brain Mapp       Date:  2017-06-28       Impact factor: 5.038

6.  Abnormal brain development in child and adolescent carriers of mutant huntingtin.

Authors:  Ellen van der Plas; Douglas R Langbehn; Amy L Conrad; Timothy R Koscik; Alexander Tereshchenko; Eric A Epping; Vincent A Magnotta; Peggy C Nopoulos
Journal:  Neurology       Date:  2019-08-01       Impact factor: 9.910

7.  Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice.

Authors:  Y P Deng; T Wong; C Bricker-Anthony; B Deng; A Reiner
Journal:  Neurobiol Dis       Date:  2013-08-19       Impact factor: 5.996

8.  Consistent neurodegeneration and its association with clinical progression in Huntington's disease: a coordinate-based meta-analysis.

Authors:  Imis Dogan; Simon B Eickhoff; Jörg B Schulz; N Jon Shah; Angela R Laird; Peter T Fox; Kathrin Reetz
Journal:  Neurodegener Dis       Date:  2012-08-23       Impact factor: 2.977

Review 9.  Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington's disease.

Authors:  Elizabeth H Aylward
Journal:  Mov Disord       Date:  2014-08-27       Impact factor: 10.338

Review 10.  A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.

Authors:  Jane S Paulsen; Martha Nance; Ji-In Kim; Noelle E Carlozzi; Peter K Panegyres; Cheryl Erwin; Anita Goh; Elizabeth McCusker; Janet K Williams
Journal:  Prog Neurobiol       Date:  2013-09-11       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.